secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2025-05-09T23:59:59+00:00
Accession:  0001404644-25-000044
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neurogene reports Q1 net loss of $22.6M; cash $292.6M; NGN-401 trial on track
-----------------------------------------------------------------------------

- Net loss of $22.6M for Q1 2025 vs $16.9M Q1 2024; R&D expenses rose to $17.8M from $13.5M.
- Cash, equivalents and short-term investments of $292.6M as of March 31, 2025; runway into H2 2027.
- NGN-401 gene therapy for Rett syndrome: registrational trial plan update expected in H1 2025; interim clinical data in H2 2025.
- Enrolling additional participants in Phase 1/2 trial; pediatric cohort (age 4-10, N=8) and older cohort (11+, N=3).
- Peer-reviewed publication in Science Translational Medicine validating EXACT transgene regulation technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000140464425000044/0001404644-25-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000140464425000044/ngne-20250509.htm
  HTML page:      https://secwatch.observer/filing/0001404644-25-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer